Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2.
作者信息
Herzog Charles A
机构信息
Division of Cardiology, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota; and Division of Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota.
出版信息
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2095-2096. doi: 10.2215/CJN.09470916. Epub 2016 Oct 25.
Abstract
摘要
相似文献
1
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 2.终末期肾病患者心房颤动管理中口服抗凝药的应用：裁决2
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2095-2096. doi: 10.2215/CJN.09470916. Epub 2016 Oct 25.
2
Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1.口服抗凝药在接受血液透析的终末期肾病合并心房颤动患者中的应用：结论1
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2093-2094. doi: 10.2215/CJN.08610816. Epub 2016 Oct 25.
3
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Verdict 3.终末期肾病患者心房颤动管理中口服抗凝药的应用：裁决3
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2097. doi: 10.2215/CJN.09230816. Epub 2016 Oct 25.
4
Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs?终末期肾病合并心房颤动的口服抗凝治疗：是时候对药物说“不”了吗？
Heart. 2017 Jun;103(11):807-808. doi: 10.1136/heartjnl-2016-310540. Epub 2017 Jan 9.
5
Anticoagulants in atrial fibrillation patients with chronic kidney disease.心房颤动合并慢性肾脏病患者的抗凝治疗。
Nat Rev Nephrol. 2012 Oct;8(10):569-78. doi: 10.1038/nrneph.2012.160. Epub 2012 Jul 24.
6
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Introduction.终末期肾病患者心房颤动管理中口服抗凝药的应用：引言。
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2078. doi: 10.2215/CJN.09700916.
7
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.终末期肾病患者心房颤动管理中口服抗凝药的应用：专家共识
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2079-2084. doi: 10.2215/CJN.02680316. Epub 2016 Oct 25.
8
Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.终末期肾病患者心房颤动管理中口服抗凝药的应用：反对观点
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2085-2092. doi: 10.2215/CJN.03200316. Epub 2016 Oct 25.
9
Use of Oral Anticoagulation in Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays? Response.心房颤动合并终末期肾病患者口服抗凝治疗的应用：当下需要什么？回应。
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):97-98. doi: 10.1016/j.rec.2018.08.002. Epub 2018 Aug 31.
10
Use of Oral Anticoagulation for Patients With Atrial Fibrillation and End-stage Renal Disease: What Is Needed Nowadays?心房颤动合并终末期肾病患者口服抗凝治疗的应用：当下需要什么？
Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):96-97. doi: 10.1016/j.rec.2018.07.007. Epub 2018 Aug 17.
引用本文的文献
1
Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis.种族、明显残疾与房颤合并维持性血液透析患者华法林处方相关性研究。
Am J Cardiol. 2019 Feb 15;123(4):598-604. doi: 10.1016/j.amjcard.2018.11.020. Epub 2018 Nov 24.
2
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.在慢性血液透析的心房颤动患者中比较阿哌沙班与苯丙香豆素的随机对照试验的设计与原理：AXADIA-AFNET 8研究
BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.
Zotero 插件